Tag: Callen-Lorde
NYC’s Callen-Lorde Community Health Center is pitching in to help the people of Puerto Rico
Callen-Lorde Community Health Center announced that it is sending an emergency medical response team to provide medical relief to Puerto Rico as part of Governor Andrew M. Cuomo’s Empire State Relief and Recovery Effort.
Callen-Lorde Community Health Center Readies for Expansion into Brooklyn in 2019
Callen-Lorde Community Health Center announces plans to address the growing healthcare needs of New York City’s LGBTQ communities by expanding its services into Brooklyn beginning in 2019.
Par and Perrigo Pharmaceuticals Urged to Address and Remedy the National Shortage of Injectable Oestrogen
Callen-Lorde Community Health Center is leading a national coalition – with partners from Fenway Health in Boston and Treatment Action Group in New York City – that has collected 570 signatures for a petition calling on pharmaceutical companies Par and Perrigo to address and remedy the national shortage of injectable oestrogen.
Callen-Lorde to Host Transcendence September 29th 2016
On Thursday, September 29, Callen-Lorde Community Health Center will host Transcendence, the organisation’s annual celebration of trans and gender non-conforming communities in support of Callen-Lorde’s pioneering Transgender Health Program.
New Facility Will Serve Ever-Expanding Health Care Needs of New York City’s LGBTQ Communities
Callen-Lorde Community Health Center announces the opening of its newest facility, Callen-Lorde Bronx. Callen-Lorde Bronx provides primary care, HIV care, transgender care and hormone therapy, lesbian and bisexual women’s health care, young adult care, sexual health care, and short-term mental health services. Patients also have access to a convenient on-site pharmacy.
Shortage Of Injectable Oestrogen Presents Possible Public Health Risk
Callen-Lorde Community Health Center warns of potential public health risk for transgender women and transfeminine people due to a U.S nationwide shortage of some generic and brand name injectable oestrogen. Makers of the drugs have reported manufacturing delays in getting the medications to the market.